bioRxivPharmacology & Toxicology
A phenomics approach for in vitro antiviral drug discovery
J. Rietdijk, M. Tampere, A. Pettke, P. Georgiev, M. Lapins, U. Warpman Berglund, O. Spjuth, M.-R. Puumalainen, J. Carreras-Puigvert
Abstract
BackgroundThe current COVID-19 pandemic has highlighted the need for new and fast methods to identify novel or repurposed therapeutic drugs. Here we present a method for untargeted phenotypic drug screening of virus-infected cells, combining Cell Painting with antibody-based detection of viral infection in a single assay. We designed an image analysis pipeline for segmentation and classification of virus-infected and non-infected cells, followed by extraction of morphological properties. ResultsWe show that the methodology can successfully capture virus-induced phenotypic signatures of MRC-5 human lung fibroblasts infected with Human coronavirus 229E (CoV-229E). Moreover, we demonstrate that our method can be used in phenotypic drug screening using a panel of nine host- and virus-targeting antivirals. Treatment with effective antiviral compounds reversed the morphological profile of the host cells towards a non-infected state. ConclusionsThe method can be used in drug discovery for morphological profiling of novel antiviral compounds on both infected and non-infected cells.
- organism: human
- assay: imaging
- research focus: drug response / drug discovery
- approach: microscopy & imaging analysis
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Morphological cell profiling for drug repurposing against SARS-CoV-2 infection
Elin Asp, Jonne Rietdijk, … Päivi Östling·bioRxiv·Aug 28, 2025
- Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19
C. Mirabelli, J. W. Wotring, … J. Z. Sexton·Proceedings of the National Academy of SciencesPeer-reviewed·Aug 19, 2021
- Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2
Katie Heiser, Peter McLean, … Christopher C. Gibson·bioRxiv·Apr 21, 2020
- Cell-based high-content approach for SARS-CoV-2 neutralization identifies unique monoclonal antibodies and PI3K pathway inhibitors.
Carly R. Cabel, Briana A. Guzman, … Curtis A. Thorne·Frontiers in Cell and Developmental BiologyPeer-reviewed·May 22, 2025
- Arrayed multicycle drug screens identify broadly acting chemical inhibitors for repurposing against SARS CoV 2
L. P. Murer, R. Volle, … U. F. Greber·bioRxiv·Mar 30, 2021
- Development and optimisation of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures
W. Chiu, L. Verschueren, … E. Van Damme·bioRxiv·Feb 2, 2022